DEC 05, 2019 5:00 AM PST

The clinical implications of high sensitive assays for HBsAg

Sponsored by: Abbott
C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Associate Medical Director, Infectious Diseases - Abbott Diagnostics
    Biography
      Born in Roma (Italy), February 10th,1956. Medical degree "cum laude" July 1980. Specialty in Gastrointestinal Diseases, July 1984. PhD in Infectious Diseases, July 1988. Associate Director Medical & Scientific Affairs, at Abbott Diagnostics with global responsibility for Infectious Diseases. Member of Italian and European Associations for the Study of the Liver (AISF, EASL); European Society of Clinical Microbiology and Infectious Diseases (ESCMID); Italian Society of Virology (ISV/SIV); Italian Blood Transfusion Society (SIMTI); European Society of Cardiology (ESC); American Association for Clinical Chemistry (AACC).

      Main research activities in Infectious Diseases: development and validation of an off-label procedure for human immunodeficiency virus (HIV) antibody avidity as a tool for identifying recent infections; clinical usefulness of hepatitis C virus core antigen (HCVAg) in diagnosis and monitoring, including health economic perspectives; quantitative serological biomarkers for hepatitis B virus (HBV) infection. Author or coauthor of 234 scientific papers, of which 73 on international, peer-reviewed journals, and about 25 congress proceedings. Adjunct professor ("Sapienza" University of Roma) at postgraduate schools in Clinical Microbiology (years 1994-1999) and Clinical Pathology (1997 and 2001-2007). Seminars on infectious diseases diagnosis at the National Institute of Health (Roma, Italy) in 1996 and 2002-2003.

    Abstract
    DATE:  December 5, 2019
    TIME:   5:00am PST, 8:00am EST
     
    The diagnosis of an active infection by the hepatitis B virus (HBV) relies on testing for the HBV surface antigen (HBsAg). Over the decades the sensitivity of HBsAg assays has increased, and the most recent solutions attain a level of 5 mIU/mL and enable to detect active HBV also at very low level of expression, with HBV-DNA levels <100 mIU/mL. The availability of such assays will help improve the safety of blood screening in settings that do not encompass testing for HBV-DNA and will enable unveiling HBsAg in a substantial share of "occult" or "latent" HBV infections (OBI). Unveiling OBIs has a great clinical relevance in immunocompromised or immunosuppressed patients and in people coinfected by other viruses, such as HCV or HIV. Additionally, since the negativity for HBsAg is a major endpoint for antiviral treatment with nucleosi(t)ide analogues, a higher sensitivity for HBsAg can help with a safer interruption of treatment.
     
    Learning Objectives:
    • Review the natural history of HBV infection and the progress in HBsAg testing
    • Understand the mechanism and clinical implications of HBV reactivation
    • Acknowledge the medical improvements linked to a better sensitivity for HBsAg
     
     
    Webinars will be available for unlimited on-demand viewing after live event.
     
    LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.

    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    OCT 08, 2020 7:00 AM PDT
    C.E. CREDITS
    OCT 08, 2020 7:00 AM PDT
    DATE: October 8, 2020 TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop thinking about ho...
    AUG 25, 2020 8:00 AM PDT
    C.E. CREDITS
    AUG 25, 2020 8:00 AM PDT
    DATE: August 25, 2020 TIME: 8:00am PDT, 10:00am CDT, 11:00am EDT Recombinant lentivirus (LV) and adeno-associated virus (AAV) are critical components of cell and gene therapies, which show g...
    MAY 08, 2020 10:00 AM PDT
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    JUN 09, 2020 10:00 AM PDT
    C.E. CREDITS
    JUN 09, 2020 10:00 AM PDT
    DATE: June 9, 2020 TIME: 10:00am PT, 1:00pm ET The presentation will first discuss sepsis as a disease and then explain the importance of performing diagnostic tests in the clinical labora...
    NOV 18, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    Loading Comments...
    Show Resources